- Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- Arcellx Provides First Quarter 2024 Financial Results
- Arcellx to Participate in Two Upcoming Investor Conferences
- Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
More ▼
Key statistics
On Friday, Arcellx Inc (ACLX:NSQ) closed at 50.78, 65.19% above the 52 week low of 30.74 set on Jul 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 50.85 |
---|---|
High | 51.88 |
Low | 50.13 |
Bid | 47.66 |
Offer | 55.50 |
Previous close | 51.34 |
Average volume | 387.28k |
---|---|
Shares outstanding | 53.50m |
Free float | 42.70m |
P/E (TTM) | -- |
Market cap | 2.77bn USD |
EPS (TTM) | -1.04 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼